Cg Oncology, Inc.
A clinical-stage oncolytic immunotherapy company, CG Oncology develops genetically engineered viruses that selectively infect and destroy bladder cancer cells while rallying the body's immune system to attack tumors. Its lead candidate, cretostimogene, is designed to treat bladder cancer while sparing patients from bladder-removal surgery. Founded in California in 2010 as Cold Genesys — a name born from its virus-based technology — the company rebranded as CG Oncology in 2020, keeping "CG" as a nod to its origins.
Sold 100.0K
Bought 1.89M
Granted 167.5K
Granted 20.0K · Sold 20.0K
Granted 99.0K · Sold 99.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Song Hong FangDirector · 4 transactions | — | 7.04M | — | — | 100.0K |
| Liu Brian Guan-ChyunDirector · 2 transactions | — | 1.89M | — | 1.89M | — |
| Kuan ArthurChief Executive Officer, Director · 4 transactions | +455.3% | 200.8K | 167.5K | — | — |
| Post Leonard EDirector · 16 transactions | +150% | 5.0K | 20.0K | — | 20.0K |
| Mulay JamesDirector · 27 transactions | — | 0 | 99.0K | — | 99.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +1.67M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.